85-5716-80　MLi-2 1mg　CAS No:1627091-47-7　456383

特徴

• MLi-2 is a leucine-rich repeat kinase 2 (LRRK2) inhibitor and may be used in the treatment and prevention of Parkinson’s disease as its a precursor to the illness. A brain-penetrant inhibitor of leucin-rich repeat kinase 2 (LRRK2) with IC50 = 0.76nM and anti-parkinsonian activity. Gain-of-function mutations in LRRK2 gene lead to increased familial and idiopathic risk of developing the disease. The inhibitors of the kinase activity have therapeutic potential against Parkinson’s disease.
• Synonyms:rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidyl]-5-[(1-methylcyclopropyl)oxy]-1H-indazole
• Molecular Formula:C₂₁H₂₅N₅O₂
• Molecular Weight:379.46
• Appearance:White to off-white powder
• Purity:≥98%
• Identity (1H NMR):Conforms to structure
• Elemental analysis (C,H,N) (on dry basis):C: 66.07-66.87%, H: 6.24-7.04%, O:18.06-18.86%
• Biological Activity:Potent and selective LRRK2 inhibitor (IC50 = 0.76-3.4nM depending on assay). Exhibits >295-fold selectivity for over 300 kinases and a diverse panel of receptors and ion channels. Centrally bioavailable and active in vivo.
• Solubility:DMSO, 50mM
• Storage and Stability:Store at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.